WC Varones

A tip of the hat to The ALNY Blog and its sometimes cryptic author who has encouraged his devoted readers to buy Alnylam Pharmaceuticals.

It's paid off:

Shares of Alnylam Pharmaceuticals were on fire Monday, rocketing more than 50% on news that the biotech group had signed a collaboration deal with Swiss drugmaker Roche potentially worth more than $1 billion.

Cambridge, Mass.-based Alnylam shares were up 52% at $22.97 in late morning trading.